Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.88 |
| ▸ | CNR2 | P34972 | 8/20 | 0.82 |
| ▸ | CNR1 | P21554 | 5/20 | 0.82 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.82 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.82 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.82 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.82 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.82 |
| ▸ | MLNR | O43193 | 1/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.82 |
| ▸ | PDE9A | O76083 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | LDHA | P00338 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24449664 | 1.00 | OPRM1 (0.88) | OPRM1CNR2CNR1TRPV1CYP1A1 | |
| SCHEMBL25878176 | 1.00 | OPRM1 (0.88) | OPRM1CNR2CNR1TRPV1CYP1A1 | |
| SCHEMBL19176351 | 1.00 | OPRM1 (0.88) | OPRM1CNR2CNR1TRPV1CYP1A1 | |
| SCHEMBL29351701 | 1.00 | OPRM1 (0.88) | OPRM1CNR2CNR1TRPV1CYP1A1 | |
| SCHEMBL13214117 | 1.00 | OPRM1 (0.88) | OPRM1CNR2CNR1TRPV1CYP1A1 | |
| SCHEMBL25341318 | 0.99 | OPRM1 (0.86) | OPRM1CNR2CNR1TRPV1CYP1A1 | |
| SCHEMBL25560685 | 0.97 | OPRM1 (0.82) | OPRM1CNR2CNR1TRPV1CYP1A1 | |
| SCHEMBL30018283 | 0.94 | OPRM1 (1.00) | OPRM1CNR2CNR1TRPV1CYP1A1 | |
| SCHEMBL23083008 | 0.94 | OPRM1 (1.00) | OPRM1CNR2CNR1TRPV1CYP1A1 | |
| SCHEMBL20658115 | 0.94 | OPRM1 (1.00) | OPRM1CNR2CNR1TRPV1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707444-B2 | Antiviral composition for SARS-CoV-2 containing cannabinoids as active ingredient | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2023-07-25 | — | — | US | disclosed |
| US-11707444-B2 | Antiviral composition for SARS-CoV-2 containing cannabinoids as active ingredient | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2023-07-25 | — | — | US | disclosed |
| US-20230131989-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USING FOR THE TREATMENT OF NON-EOSINOPHILIC INFLAMMATION AND INFLAMMATORY DISORDERS | MEDTERRA PHARMA LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230131989-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USING FOR THE TREATMENT OF NON-EOSINOPHILIC INFLAMMATION AND INFLAMMATORY DISORDERS | MEDTERRA PHARMA LLC | 2023-04-27 | — | — | US | disclosed |
| US-11542226-B2 | Polyfunctional cannabinoids | Axim Biotechnologies, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210332004-A1 | POLYFUNCTIONAL CANNABINOIDS | AXIM BIOTECHNOLOGIES INC (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2021076197-A1 | CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20190345087-A1 | BIO-STABLE CANNABINOID COMPOUNDS AND METHODS FOR ENHANCING THEIR PHYSIOLOGICAL CONCENTRATION | TUATARA CAPITAL FUND I, L.P. | 2019-11-14 | — | — | US | disclosed |
| US-10384997-B2 | Bio-stable cannabinoid compounds and methods for enhancing their physiological concentration | TEEWINOT TECHNOLOGIES LIMITED (IE) | 2019-08-20 | — | — | US | disclosed |
| US-20180201560-A1 | BIO-STABLE CANNABINOID COMPOUNDS AND METHODS FOR ENHANCING THEIR PHYSIOLOGICAL CONCENTRATION | TUATARA CAPITAL FUND I, L.P. | 2018-07-19 | — | — | US | disclosed |
| US-20180201560-A1 | BIO-STABLE CANNABINOID COMPOUNDS AND METHODS FOR ENHANCING THEIR PHYSIOLOGICAL CONCENTRATION | TUATARA CAPITAL FUND I, L.P. | 2018-07-19 | — | — | US | disclosed |
| WO-2017091764-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CONSTANCE THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10384997-B2 | Bio-stable cannabinoid compounds and methods for enhancing their physiological concentration | CNR1, CNR2, FAAH | OPRM1 15/4885CNR2 2/4885CNR1 1/4885 |
| US-20230131989-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USING FOR THE TREATMENT OF NON-EOSINOPHILIC INFLAMMATION AND INFLAMMATORY DISORDERS | CNR2, CNR1, FAAH2 | OPRM1 515/4885CNR2 1/4885CNR1 2/4885 |
| US-20180201560-A1 | BIO-STABLE CANNABINOID COMPOUNDS AND METHODS FOR ENHANCING THEIR PHYSIOLOGICAL CONCENTRATION | CNR1, CNR2, FAAH | OPRM1 15/4885CNR2 2/4885CNR1 1/4885 |
| US-11542226-B2 | Polyfunctional cannabinoids | CNR2, CNR1, GPR18 | OPRM1 8/4885CNR2 1/4885CNR1 2/4885 |
| US-20190345087-A1 | BIO-STABLE CANNABINOID COMPOUNDS AND METHODS FOR ENHANCING THEIR PHYSIOLOGICAL CONCENTRATION | CNR1, CNR2, FAAH | OPRM1 30/4885CNR2 2/4885CNR1 1/4885 |
| US-20210332004-A1 | POLYFUNCTIONAL CANNABINOIDS | CNR2, CNR1, GPR18 | OPRM1 8/4885CNR2 1/4885CNR1 2/4885 |
| US-11707444-B2 | Antiviral composition for SARS-CoV-2 containing cannabinoids as active ingredient | TMPRSS2, ACE2, CNR2 | OPRM1 37/4885CNR2 3/4885CNR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.